Collegium Pharmaceutical, Inc. (COLL) – What Are Investment Firms Saying About This Stock?

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned an average rating of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $44.88.

Several brokerages have recently commented on COLL. Truist Financial began coverage on Collegium Pharmaceutical in a research report on Wednesday, September 9th. They issued a “buy” rating and a $49.00 target price for the company. Barclays dropped their price target on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 19th. Needham & Company LLC reduced their price objective on Collegium Pharmaceutical from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Collegium Pharmaceutical in a report on Friday. Finally, Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday.

Key Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Q3 adjusted earnings of $1.96 per share topped consensus estimates, and revenue of $216.3 million narrowly beat expectations. The company reported record quarterly revenue, including JORNAY PM revenue up 24% year over year. Collegium Q3 2026 results
• Positive Sentiment: FY 2026 revenue guidance is $825 million–$855 million, a range whose midpoint is above the $832.9 million consensus estimate. Collegium also announced a $50 million accelerated share repurchase. Collegium Q3 2026 results
• Neutral Sentiment: Needham lowered its price target from $46 to $44 but maintained a Buy rating, indicating continued optimism alongside a more cautious valuation. Needham lowers Collegium price target
• Negative Sentiment: Piper Sandler cut its target sharply, from $43 to $28, and assigned a Neutral rating. The lower valuation outlook could weigh on sentiment despite the target remaining above the referenced share price. Piper Sandler rating
• Negative Sentiment: EPS declined from $2.25 in the year-ago quarter to $1.96, tempering the earnings beat. Collegium Q3 earnings

Collegium Pharmaceutical Stock Down 3.8%

Shares of Collegium Pharmaceutical stock traded down $0.95 during trading on Friday, reaching $24.21. The company had a trading volume of 775,375 shares, compared to its average volume of 622,329. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. Collegium Pharmaceutical has a fifty-two week low of $21.43 and a fifty-two week high of $50.79. The firm’s fifty day moving average is $22.99 and its 200-day moving average is $32.79. The company has a market cap of $788.28 million, a price-to-earnings ratio of 24.21, a price-to-earnings-growth ratio of 0.74 and a beta of 0.75.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.10. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The firm had revenue of $216.34 million during the quarter, compared to analyst estimates of $216.03 million. During the same period in the previous year, the company earned $2.25 earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 67.4% on a year-over-year basis. On average, analysts anticipate that Collegium Pharmaceutical will post 6.42 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. grew its position in shares of Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 418 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Collegium Pharmaceutical during the third quarter worth about $36,000. Assetmark Inc. lifted its holdings in Collegium Pharmaceutical by 9.3% in the first quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 335 shares during the last quarter. Allworth Financial LP bought a new position in Collegium Pharmaceutical in the second quarter worth about $175,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in Collegium Pharmaceutical by 20.6% in the first quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock worth $167,000 after acquiring an additional 861 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.